- Home
- RIGL vs GSBC Comparison
RIGL vs GSBC Comparison
Compare RIGL & GSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | GSBC |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 673.5M |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RIGL | GSBC |
|---|---|---|
| Price | $34.56 | $61.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $43.20 | ★ $60.50 |
| AVG Volume (30 Days) | ★ 257.9K | 56.1K |
| Earning Date | 04-01-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.70% |
| EPS Growth | ★ 807.14 | N/A |
| EPS | ★ 5.38 | 4.74 |
| Revenue | ★ $179,278,000.00 | N/A |
| Revenue This Year | $66.81 | N/A |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | ★ $6.66 | $13.49 |
| Revenue Growth | ★ 53.38 | N/A |
| 52 Week Low | $15.50 | $47.57 |
| 52 Week High | $52.24 | $67.70 |
Technical Indicators
Market Signals| Indicator | RIGL | GSBC |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 43.46 |
| Support Level | $33.05 | $61.48 |
| Resistance Level | $36.95 | $63.44 |
| Average True Range (ATR) | 1.46 | 1.55 |
| MACD | 0.24 | -0.18 |
| Stochastic Oscillator | 39.78 | 10.79 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.